Dr. Nicholas Livingston

At the conclusion of this activity participants will be able to:
1.         Describe MOUD treatment policy exemptions and implementation during the COVID-19 Public Health Emergency
2.         Describe national trends in access to and continuous use of medications for opioid use disorder (MOUD; Methadone, Buprenorphine) during COVID-19
3.         Discuss patient and provider perspectives regarding MOUD access, receipt, and quality during the COVID-19 pandemic
4.         Discuss elements of patient-centered care and future directions for MOUD in the post-COVID-19 era

 

Dr. Livingston is a consultant for Atai and Pear Therapeutics.He receives research support from Damaji Therapeutics.

Session date: 
03/08/2023 - 8:00am to 9:00am EST
Location: 
Crosstown 2nd Floor – Seminar 2128
801 Mass Ave
Boston, MA 02118
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Participation
Please login or register to take this course.